Aggregate-selective removal of pathological tau by clustering-activated degraders

Jonathan Benn(UK Dementia Research Institute), Shi Cheng(UK Dementia Research Institute), Sophie Keeling(UK Dementia Research Institute), Annabel E. Smith(UK Dementia Research Institute), Marina Vaysburd(MRC Laboratory of Molecular Biology), Dorothea Böken(UK Dementia Research Institute), Lauren V. C. Miller(MRC Laboratory of Molecular Biology), Panagiotis Katsinelos(MRC Laboratory of Molecular Biology), Catarina Franco(MRC Laboratory of Molecular Biology), Elian Dupré(Centre National de la Recherche Scientifique), Clément Danis(Centre National de la Recherche Scientifique), Isabelle Landrieu(Centre National de la Recherche Scientifique), Luc Buée(Inserm), David Klenerman(UK Dementia Research Institute), Leo C. James(MRC Laboratory of Molecular Biology), William A. McEwan(UK Dementia Research Institute)
Science
August 29, 2024
Cited by 64Open Access
Full Text

Abstract

Selective degradation of pathological protein aggregates while sparing monomeric forms is of major therapeutic interest. The E3 ligase tripartite motif-containing protein 21 (TRIM21) degrades antibody-bound proteins in an assembly state-specific manner due to the requirement of TRIM21 RING domain clustering for activation, yet effective targeting of intracellular assemblies remains challenging. Here, we fused the RING domain of TRIM21 to a target-specific nanobody to create intracellularly expressed constructs capable of selectively degrading assembled proteins. We evaluated this approach against green fluorescent protein-tagged histone 2B (H2B-GFP) and tau, a protein that undergoes pathological aggregation in Alzheimer's and other neurodegenerative diseases. RING-nanobody degraders prevented or reversed tau aggregation in culture and in vivo, with minimal impact on monomeric tau. This approach may have therapeutic potential for the many disorders driven by intracellular protein aggregation.


Related Papers